We do have Covid19 IgG/IgM Immunoassay rapid tests to fight the pandemic
0

Your Cart is Empty

It begins in Tokyo - History of TXA, a drug which saves millions of mother lives from postpartum hemorrhage

December 26, 2017

It begins in Tokyo - History of TXA, a drug which saves millions of mother lives from postpartum hemorrhage

It started with a Japanese wife and husband team in Tokyo in the 1950s. Postpartum hemorrhage was a leading cause of maternal death in Japan at the time, and Utako and Shosuke Okamoto set out to identify a drug that could reduce the number of mothers dying during childbirth. Resources were hard to find at the time, especially for something like blood research. On top of that, the heavily male-dominated medical field meant that Utako had to work twice as hard and long for the chance to even be acknowledged for her accomplishments. After giving birth, she had to bring her baby into the lab because the system did not support working mothers.

Their hard work paid off. They knew that there was already an enzyme in the blood that broke down clots - they just needed to figure out how to get that enzyme going. The amino acid lysine was found to be effective, but they kept looking, thinking there must be more. In 1962, they published in the Keio Journal of Medicine about a drug called tranexamic acid (TXA), which they discovered to be 27 times more powerful than a previous lysine-based drug. Despite this, local obstetricians were not too interested and tranexamic acid was eventually marketed to easy heavy menstrual bleeding and bleeding from procedures such as tooth extractions.

Years later, research finally recognized the full extent of what TXA could do for trauma patients. In 2010, results of the CRASH-2 trial was published in the Lancet. Researchers found that out of over 10,000 study participants, TXA significantly reduced the risk of death due to bleeding. Earlier this year, the WOMAN trial focused specifically on pregnant women and found that TXA significantly reduced death due to postpartum hemorrhage as well. Utako passed away shortly after recruiting for the WOMAN study reached its goal of 20,000 participants, but she said she already knew the results. “I am absolutely sure that it’s going to be effective - I don’t need the research to know this.”

By Vivian Shih


Leave a comment

Comments will be approved before showing up.


Also in The Maternova blog

Stunting and Linear Growth Faltering Causes Small Babies in the Next Generation
Stunting and Linear Growth Faltering Causes Small Babies in the Next Generation

February 26, 2020

A quick review of child stunting and linear growth retardation and its association with lifelong morbidity and mortality.     The WHO definition of stunting is: "Children are  defined  as  stunted  if their height-for-age is more than two standard deviations below the WHO Child Growth Standards median."  Stunting is associated with girls later giving birth to small for gestational age babies. 
Read More
NovaVeil in two additional pilots garners high user acceptability from mothers
NovaVeil in two additional pilots garners high user acceptability from mothers

February 05, 2020

Maternova recently distributed a large number of our NovaVeil apparel in the New Life Birth Center in Uganda, a maternity center in an urban slum where malaria is endemic and the poverty rate means that people are living on less than $2 per day.
Read More
Breastfeeding and Neurodevelopment  
Breastfeeding and Neurodevelopment  

January 30, 2020

The consumption of breastmilk in early life allows for the colonization of the infant’s microbiota, a crucial step during the beginning of life, not just for survival, but for long-term health as well. 
Read More
News & Updates

Sign up to get the latest on sales, new releases and more …

maternal and newborn health news